Log in

LON:AVOAdvanced Oncotherapy Share Price, Forecast & News

GBX 25.20
+0.20 (+0.80 %)
(As of 07/14/2020)
Today's Range
Now: GBX 25.20
50-Day Range
MA: GBX 25.75
52-Week Range
Now: GBX 25.20
Volume77,456 shs
Average Volume79,755 shs
Market Capitalization£77.21 million
P/E RatioN/A
Dividend YieldN/A
Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also rents a medical facility. It has operations in the United Kingdom, Switzerland, and the Unites States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy PLC was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More
Advanced Oncotherapy logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars

Industry, Sector and Symbol

Industry Medical Devices



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 1.09 per share
Book ValueGBX 17.60 per share



Market Cap£77.21 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 25.20
+0.20 (+0.80 %)
(As of 07/14/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive AVO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Advanced Oncotherapy (LON:AVO) Frequently Asked Questions

How has Advanced Oncotherapy's stock been impacted by COVID-19 (Coronavirus)?

Advanced Oncotherapy's stock was trading at GBX 32.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVO stock has decreased by 22.5% and is now trading at GBX 25.20.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Advanced Oncotherapy?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanced Oncotherapy in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Advanced Oncotherapy

How were Advanced Oncotherapy's earnings last quarter?

Advanced Oncotherapy PLC (LON:AVO) posted its quarterly earnings results on Monday, June, 29th. The company reported ($9.83) EPS for the quarter, missing analysts' consensus estimates of ($8.90) by $0.93.
View Advanced Oncotherapy's earnings history

What price target have analysts set for AVO?

1 Wall Street analysts have issued 12-month target prices for Advanced Oncotherapy's shares. Their forecasts range from GBX 155 to GBX 155. On average, they anticipate Advanced Oncotherapy's share price to reach GBX 155 in the next year. This suggests a possible upside of 515.1% from the stock's current price.
View analysts' price targets for Advanced Oncotherapy

Has Advanced Oncotherapy been receiving favorable news coverage?

Press coverage about AVO stock has trended somewhat negative on Tuesday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advanced Oncotherapy earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Advanced Oncotherapy

Who are some of Advanced Oncotherapy's key competitors?

What other stocks do shareholders of Advanced Oncotherapy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), BMR Group (BMR), GW Pharmaceuticals PLC- (GWPH), Lancashire (LRE), Oxford BioMedica (OXB), Sirius Minerals (SXX), Renishaw (RSW), Scancell (SCLP) and Tullow Oil (TLW).

Who are Advanced Oncotherapy's key executives?

Advanced Oncotherapy's management team includes the following people:
  • Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 76)
  • Mr. Nicolas Serandour, CEO & Exec. Director
  • Mr. Ed Lee, COO & Sr. VP of Operations
  • Mr. Graham Pughe, Sr. Vice-Pres, Accounting & IT
  • Ms. Geraldine Poindron, Corp. Fin. Mang.

What is Advanced Oncotherapy's stock symbol?

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

How do I buy shares of Advanced Oncotherapy?

Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Advanced Oncotherapy's stock price today?

One share of AVO stock can currently be purchased for approximately GBX 25.20.

How big of a company is Advanced Oncotherapy?

Advanced Oncotherapy has a market capitalization of £77.21 million. Advanced Oncotherapy employs 93 workers across the globe.

What is Advanced Oncotherapy's official website?

The official website for Advanced Oncotherapy is www.advancedoncotherapy.com.

How can I contact Advanced Oncotherapy?

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.